Major Norwegian university hospital contributing clinical cohorts, biobanks, and trial infrastructure to European immunology, respiratory, and personalized medicine research.
Haukeland University Hospital is one of Norway's largest teaching hospitals, serving as a clinical research hub in Bergen. In H2020, they contribute patient cohorts, clinical trial infrastructure, and biobank access across immunology, respiratory medicine, oncology, and paediatric research. They frequently act as a clinical validation site — providing real-world patient data, biological samples, and clinical expertise to large European research consortia. Their work bridges laboratory science and bedside application, particularly in immune-related diseases, cancer treatment, and personalized medicine.
Central to 3TR (autoimmunity, inflammation, stratification), INCENTIVE (influenza vaccine immune profiling), AML-VACCiN (dendritic-cell vaccine for leukaemia), and BruSH (immunology, endotoxin).
ALEC studied lung growth and COPD risk factors in cohorts; BRuSH investigates oral microbiome impact on respiratory health; INCENTIVE targets influenza in vulnerable populations.
PedCRIN built paediatric clinical research networks; c4c is a major collaborative network for European clinical trials in children; both focus on trial infrastructure and best practices.
SC0806 addressed spinal cord injury with surgical implantation of biomaterials; MAXIBONE works on personalized maxillofacial bone regeneration using mesenchymal stem cells and 3D-printed biomaterials.
FORECEE focused on female cancer prediction using cervical omics; ISPIC on image-guided surgery and postoperative immunotherapy; AML-VACCiN on dendritic-cell vaccine therapy for acute myeloid leukaemia.
BrainGutAnalytics (their sole coordinated project) applies multiomics to the brain-gut axis; 3TR uses single-cell data, integrative genomics, and predictive modeling for disease stratification.
In their early H2020 period (2015–2017), Haukeland focused on established clinical domains — respiratory disease cohorts (ALEC, COPD risk factors), cancer prediction (FORECEE), and surgical interventions for spinal cord injury and leukaemia. From 2018 onward, their portfolio shifted toward data-intensive personalized medicine: multi-omics analysis (BrainGutAnalytics), immune stratification and predictive modeling (3TR), microbiome research (BRuSH), and next-generation vaccine development (INCENTIVE). This evolution reflects a hospital moving from contributing patient cohorts to actively driving computational and molecular-level clinical research.
Haukeland is increasingly positioning itself at the intersection of clinical data, omics technologies, and immune-mediated disease stratification — expect future work in precision immunology and biomarker-driven treatment selection.
Haukeland overwhelmingly joins projects as a participant (7) or third party (6), having coordinated only once (BrainGutAnalytics). This is typical for a university hospital that contributes clinical infrastructure, patient access, and specialized expertise to consortia led by others. With 227 unique partners across 30 countries, they are a highly networked clinical node — valued for what they bring to the table (cohorts, biobanks, trial sites) rather than for project management leadership.
With 227 unique consortium partners across 30 countries, Haukeland maintains one of the broadest clinical collaboration networks among Norwegian hospitals. Their partnerships span all of Europe and extend to global consortia like INCENTIVE (Indo-European vaccine collaboration).
Haukeland combines the clinical depth of a major Nordic university hospital with unusually broad European research integration — 14 H2020 projects across immunology, oncology, respiratory, and paediatric medicine. Their strength is providing well-characterized patient cohorts, biobank samples, and clinical trial sites within a trusted Scandinavian healthcare system known for high-quality patient registries. For consortium builders, they offer reliable clinical validation capacity in a country with excellent health data infrastructure and strong regulatory frameworks.
